Effects of Low-dose Intramuscular Ketorolac on Experimental Pain in the Masseter Muscle of Healthy Women

Aims: To investigate the effect of a low dose of intramuscular (im) ketorolac compared with lidocaine (LA) in a double-blinded, randomized, and controlled trial. Methods: Twelve healthy women participated in three sessions and received two injections into their right masseter muscle per session. The first injections contained hypertonic saline (HS, 5% in 0.2 mL) to induce muscle pain. The second injections were given 30 minutes later and contained, together with HS, either ketorolac (3 mg in 0.2 mL), LA (2% lidocaine in 0.2 ml), or HS alone (control). HS-evoked pain intensity was scored on a 0 to 10 electronic visual analog scale (VAS) measuring peak, duration, and area under the curve (AUC). Pressure pain thresholds (PPT), pressure pain tolerance levels (PPTOL), and pain on palpation (POP) were determined bilaterally on the masseter muscle before and 5, 15, and 25 minutes after the injections. Maximum jaw opening (MJO) was measured at baseline and every 10 minutes after. McGill Pain Questionnaire (MPQ) scores and the extent of the HS-evoked pain (pain drawings) were recorded at baseline, 2 minutes after the first and second injections, and every 10 minutes during the entire experimental session. Results: There were no differences between the three sessions in HS-evoked pain measures from the first injection (P > .05). During the second injection, HS + LA demonstrated significantly lower VAS peak, duration, and AUC scores than control and HS + ketorolac (P < .001). In the HS + ketorolac session, the VAS AUC was significantly lower than in the control session (P < .005). The sessions had no main effect on PPT, PPTOL, POP, MJO, or pain drawings (P > .05). Conclusion: A low dose of im ketorolac has a significant and immediate analgesic effect on HS-evoked jaw muscle pain but significantly less than LA. A local anesthetic-like effect may be the underlying mechanism.

experimental muscle pain;ketorolac;local anesthetics;NSAIDs;trigeminal nociception

1. LeResche L. Epidemiology of temporomandibular disorders: Implications for the investigation of etiologic factors. Crit Rev Oral Biol Med 1997;8:291–305.

2. Fillingim RB, Maixner W. Sex-related factors in temporomandibular disorders. In: Fillingim RB (ed). Sex, Gender and Pain. Seattle: IASP, 2000:309–325. 3. Carlsson GE, LeResche L. Epidemiology of temporomandibular disorders. In: Sessle B, Bryant P, Dionne R (eds). Temporomandibular Disorders and Related Pain Conditions. Seattle: IASP, 1995:497–506.

4. Drangsholt M, LeResche L. Temporomandibular disorder pain. In: Crombie IK (ed). Epidemiology of Pain. Seattle: IASP, 1999:497–506.

5. Dao TT, LeResche L. Gender differences in pain. J Orofac Pain 2000;14:169–184.

6. Curatolo M, Bogduk N. Pharmacologic pain treatment of musculoskeletal disorders: Current perspectives and future prospects. Clin J Pain 2001;17:25–32.

7. Stohler CS. Clinical perspectives on masticatory and related muscle disorders. In: Sessle BJ, Bryant PS, Dionne RA (eds). Temporomandibular Disorders and Related Pain Conditions. Seattle: IASP, 1995:3–29.

8. Singer E, Dionne R. Controlled evaluation of ibuprofen and diazepam for chronic orofacial muscle pain. J Orofac Pain 1997;11:139–146.

9. Dionne RA. Pharmacologic treatments for temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:134–142.

10. Svensson P. Orofacial musculoskeletal pain. In: Giamberardino MA (ed). Pain 2002, An Updated Review: Refresher Course Syllabus. Seattle: IASP, 2002:447–458.

11. Gotzsche PC. Non-steroidal antiinflammatory drugs. BMJ 2000;320:1058–1061.

12. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996;52:13–23.

13. Walker JS. NSAIDs: An update on their analgesic effects. Clin Exp Pharmacol Physiol 1995;22:855–860.

14. Gordon SM, Brahim JS, Rowan J, Kent A, Dionne RA. Peripheral prostanoid levels and nonsteroidal anti-inflammatory drug analgesia: Replicate clinical trials in a tissue injury model. Clin Pharmacol Ther 2002;72:175–183.

15. Cairns BE, Mann MK, Mok E, Dong XD, Svensson P. Di-clofenac exerts local anesthetic-like actions on rat masseter muscle afferent fibers. Brain Res 2008;1194:56–64.

16. Dong XD, Svensson P, Cairns BE. The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism. Pain 2009;147:36–45.

17. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333–338.

18. Galer BS, Rowbotham M, Perander J, Devers A, Friedman E. Topical diclofenac patch relieves minor sports injury pain: Results of a multicenter controlled clinical trial. J Pain Symp Manag 2000;19:287–294.

19. Di Rienzo Businco L, Di Rienzo Businco A, D’Emilia M, Lau-riello M, Coen Tirelli G. Topical versus systemic diclofenac in the treatment of temporomandibular joint dysfunction symptoms. Acta Otorhinolaryngol Ital 2004;24:279–285.

20. Kuo CC, Huang RC, Lou BS. Inhibition of Na(+) current by diphenhydramine and other diphenyl compounds: Mo-lecular determinants of selective binding to the inactivated channels. Mol Pharmacol 2000;57:135–143.

21. Kellgren JH. Observations on referred pain arising from muscle. Clin Sci 1938;3:175–190.

22. Svensson P, Graven-Nielsen T. Craniofacial muscle pain: Review of mechanisms and clinical manifestations. J Orofac Pain 2001;15:117–145.

23. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examina-tions and specifications, critique. J Craniomandib Disord 1992;6:301–355.

24. Svensson P, Arendt-Nielsen L, Nielsen H, Larsen JK. Effect of chronic and experimental jaw muscle pain on pain-pres-sure thresholds and stimulus-response curves. J Orofac Pain 1995;9:347–356.

25. Svensson P, Graven-Nielsen T, Arendt-Nielsen L. Mechanical hyperesthesia of human facial skin induced by tonic painful stimulation of jaw muscles. Pain 1998;74:93–100.

26. Svensson P. Effects of human jaw-muscle pain on somato sensory and motor function: Experimental studies and clinical implications [thesis]. Aarhus: Aarhus Universitet, 2000.

27. Graven-Nielsen T, Arendt-Nielsen L, Svensson P, Jensen TS. Experimental muscle pain: A quantitative study of local and referred pain in humans following injection of hypertonic saline. J Musculoskel Pain 1997;5:49–69.

28. Graven-Nielsen T, Babenko V, Svensson P, Arendt-Nielsen L. Experimentally induced muscle pain induces hypoalgesia in heterotopic deep tissues, but not in homotopic deep tissues. Brain Res 1998;787:203–210.

29. Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: Evidence from animal and human studies. Clin J Pain 2001;17:2–10.

30. Cairns BE, Svensson P, Wang K, et al. Ketamine attenuates glutamate-induced mechanical sensitization of the masseter muscle in human males. Exp Brain Res 2006;169:467–472.

31. Melzack R. The McGill pain questionnaire: Major properties and scoring methods. Pain 1975;1:277–299.

32. Drewes AM, Helweg-Larsen S, Petersen P, et al. McGill pain questionnaire translated into Danish: Experimental and clinical findings. Clin J Pain 1993;9:80–87.

33. Sherman JJ, LeResche L. Does experimental pain response vary across the menstrual cycle? A methodological review. Am J Physiol Regul Integr Comp Physiol 2006;291:245–256.

34. Isselee H, De Laat A, De Mot B, Lysens R. Pressure-pain threshold variation in temporomandibular disorder myalgia over the course of the menstrual cycle. J Orofac Pain 2002;16:105–117.

35. Drobek W, Schoenaers J, De Laat A. Hormone-dependent fluctuations of pressure pain threshold and tactile thresh-old of the temporalis and masseter muscle. J Oral Rehabil 2002;29:1042–1051.

36. Sherman JJ, LeResche L, Mancl LA, Huggins K, Sage JC, Dworkin SF. Cyclic effects on experimental pain response in women with temporomandibular disorders. J Orofac Pain 2005;19:133–143.

37. Svensson P. What can human experimental pain models teach us about clinical TMD? Arch Oral Biol 2007;52:391–394.

38. Wang K, Svensson P, Arendt-Nielsen L. Modulation of exteroceptive suppression periods in human jaw-closing muscles by local and remote experimental muscle pain. Pain 1999;82:253–262.

39. Svensson P, Cairns BE, Wang K, et al. Glutamate-evoked pain and mechanical allodynia in the human masseter muscle. Pain 2003;101:221–227.

40. Sotgiu ML, Biella G, Formaglio F, Marchettini P. Central effect of ketorolac involving NMDA receptors activity. Brain Res 1998;813:223–226.

41. Juhl GI, Svensson P, Norholt SE, Jensen TS. Long-lasting mechanical sensitization following third molar surgery. J Orofac Pain 2006;20:59–73.

42. Terkelsen AJ, Bach FW, Jensen TS. Experimental forearm immobilization in humans induces cold and mechanical hyperalgesia. Anesthesiology 2008;109:297–307.

43. Baad-Hansen L, Cairns BE, Ernberg Malin, Svensson P. Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity. Cephalalgia 2010;30:68–76.

44. Cairns BE, Gambarota G, Dunning PS, Mulkern RV, Berde CB. Activation of peripheral excitatory amino acid receptors decreases the duration of local anesthesia. Anesthesiol-ogy 2003;98:521–529.